Tag Archives: biopharmaceuticals

Challenges to the Specialty Business Model

By Emily O’Connor, Jillian Scaife, and Ryan P. Million Biopharmaceutical drug discovery companies have progressively tailored their pipelines to specialty therapeutic areas and smaller patient populations. However, the specialty business model has lately shown signs of strain and outright constraints in continued scalability. Agents such as Gleevec, Zaltrap, and Sovaldi have been under fire from […]
Posted in Biotech, Market Access, Strategy | Also tagged , , | Leave a comment

Biopharmaceuticals: Approvals Rate Best in Five Years

Overall, last year can be considered quite a successful one in terms of new product approvals. Nineteen products containing new biopharmaceutical molecular entities were approved in the United States and/or the European Union. These approval numbers are above average compared to the previous five years, which recorded a mean approval rate of 13 products. The […]
Posted in Biotech, Europe, Global, Guest Blog, Regulatory | Also tagged , | Leave a comment

Baxter Splits Biopharm and Medical Products into Two Businesses

Baxter International plans to create two separate, independent global healthcare companies, with one focused on biopharmaceuticals and the other on medical products.
Posted in Biotech, Strategy | Also tagged , | Leave a comment

Biopharma's High Performers 2014

Accenture has launched the latest version of its annual study of the biopharmaceutical industry. The High Performance Business (HPB) report analyses  the long-term performance of the 16 largest pharma companies globally, highlighting industry trends, pharmaceutical business performance analysis, and potential implications for the industry.
Posted in Biotech, Global, Strategy | Also tagged , , , , | Leave a comment

Shrinking Economy Hits California Biosector

By Amy Ritter, Pharmaeutical Technology. A report released on Feb. 8, 2012 from the California Healthcare Institute, BayBio and PwC shows that the shrinking economy, changes in investment strategies, and pressures on the pharmaceutical market have put the brakes on one of the US’s most robust biotechnology centers. California had enjoyed steady growth in its […]
Posted in Biotech, Guest Blog | Also tagged , , , | Leave a comment
  • Categories

  • Meta